{"id":"NCT03535194","sponsor":"Eli Lilly and Company","briefTitle":"A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-26","primaryCompletion":"2020-03-05","completion":"2020-06-03","firstPosted":"2018-05-24","resultsPosted":"2021-03-30","lastUpdate":"2021-03-30"},"enrollment":1484,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Mirikizumab","otherNames":["LY3074828"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Secukinumab","otherNames":[]}],"arms":[{"label":"250mg Q4W/250mg Q8W Mirikizumab","type":"EXPERIMENTAL"},{"label":"250mg Q4W/125mg Q8W Mirikizumab","type":"EXPERIMENTAL"},{"label":"Placebo/250mg Mirikizumab","type":"EXPERIMENTAL"},{"label":"300mg Secukinumab","type":"ACTIVE_COMPARATOR"},{"label":"Japan GPP/EP","type":"EXPERIMENTAL"}],"summary":"The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.","primaryOutcome":{"measure":"Percentage of Participants With a Static Physician's Global Assessment (sPGA) of (0,1) With at Least a 2-point Improvement From Baseline","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo","deltaMin":6.3,"sd":null},{"arm":"300mg Secukinumab","deltaMin":76.3,"sd":null},{"arm":"250mg Q4W Mirikizumab","deltaMin":79.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":7},"locations":{"siteCount":178,"countries":["United States","Argentina","Australia","Canada","Czechia","France","Germany","Hungary","Israel","Italy","Japan","Poland","Puerto Rico","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["38251498"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/4OGlssjkYoIKEIqGEWMso0?conditionId=5QbmZKQ9SVYRi4IGWDazJj"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":112},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Back pain","Arthralgia"]}}